Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when MYGN files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: MYGN MYRIAD GENETICS INC 8-K

Myriad Genetics discloses $1.32M severance and equity acceleration for former CCO Brian Donnelly

Filed October 9, 2026 · Period ending October 6, 2026 · ~1 min read

3 key changes

Key Changes

  • medium

    Former Chief Commercial Officer Brian Donnelly entered into a separation agreement with Myriad Genetics on October 6, 2026, following his departure effective September 16, 2026.

  • medium

    Donnelly will receive a lump sum severance payment of $1,322,294, contingent on compliance with restrictive covenants and a release of claims.

  • medium

    All outstanding time-based equity awards scheduled to vest within two years of the separation date will be accelerated and deemed vested on the separation date.

Summary

Myriad Genetics has formalized the departure of its former Chief Commercial Officer, Brian Donnelly, through a separation agreement dated October 6, 2026. The agreement provides for a lump sum severance payment of $1,322,294 and accelerates the vesting of time-based equity awards that would have vested within two years of the separation date. Performance-based awards remain outstanding and may vest if performance conditions are met within that two-year period.

The separation is a routine executive transition, with no red flags or disagreements disclosed. The severance and equity acceleration are standard elements of such agreements, and the company has not indicated any broader strategic or operational concerns. Investors should view this as a normal governance matter with no immediate financial or operational impact beyond the disclosed compensation costs.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Oct 13, 2026 · How we verify